1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.
| Descriptor ID |
D015632
|
| MeSH Number(s) |
D03.383.725.450
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine".
Below are MeSH descriptors whose meaning is more specific than "1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine".
This graph shows the total number of publications written about "1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine" by people in this website by year, and whether "1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2005 | 4 | 1 | 5 |
| 2006 | 1 | 0 | 1 |
| 2007 | 0 | 2 | 2 |
| 2009 | 0 | 2 | 2 |
| 2010 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine" by people in Profiles.
-
Smeyne RJ, Eells JB, Chatterjee D, Byrne M, Akula SM, Sriramula S, O'Rourke DP, Schmidt P. COVID-19 Infection Enhances Susceptibility to Oxidative Stress-Induced Parkinsonism. Mov Disord. 2022 07; 37(7):1394-1404.
-
Phani S, Jablonski M, Pelta-Heller J, Cai J, Iacovitti L. Gremlin is a novel VTA derived neuroprotective factor for dopamine neurons. Brain Res. 2013 Mar 15; 1500:88-98.
-
Pattarini R, Rong Y, Shepherd KR, Jiao Y, Qu C, Smeyne RJ, Morgan JI. Long-lasting transcriptional refractoriness triggered by a single exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine. Neuroscience. 2012 Jul 12; 214:84-105.
-
Gerecke KM, Jiao Y, Pani A, Pagala V, Smeyne RJ. Exercise protects against MPTP-induced neurotoxicity in mice. Brain Res. 2010 Jun 23; 1341:72-83.
-
Zigmond MJ, Cameron JL, Leak RK, Mirnics K, Russell VA, Smeyne RJ, Smith AD. Triggering endogenous neuroprotective processes through exercise in models of dopamine deficiency. Parkinsonism Relat Disord. 2009 Dec; 15 Suppl 3:S42-5.
-
Chen PC, Vargas MR, Pani AK, Smeyne RJ, Johnson DA, Kan YW, Johnson JA. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte. Proc Natl Acad Sci U S A. 2009 Feb 24; 106(8):2933-8.
-
Boyd JD, Jang H, Shepherd KR, Faherty C, Slack S, Jiao Y, Smeyne RJ. Response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra pars compacta. Brain Res. 2007 Oct 17; 1175:107-16.
-
Pattarini R, Smeyne RJ, Morgan JI. Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease. Neuroscience. 2007 Mar 16; 145(2):654-68.
-
Anderson DW, Bradbury KA, Schneider JS. Neuroprotection in Parkinson models varies with toxin administration protocol. Eur J Neurosci. 2006 Dec; 24(11):3174-82.
-
Lloyd SA, Faherty CJ, Smeyne RJ. Adult and in utero exposure to cocaine alters sensitivity to the Parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience. 2006 Feb; 137(3):905-13.